ENGN vs FTH: fair value comparison
enGene Holdings Inc. and Faeth Therapeutics, Inc. · Updated 2026-10-19
ENGN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. FTH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ENGN currently ranks higher by quality score.
| ENGN | FTH | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $1.67 | $18.80 |
| 12-month range | $1.44–$12.17 | $7.89–$40.05 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #238 of 301 Healthcare | #239 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: ENGN fair value analysis · FTH fair value analysis